Cellectis (ALCLS) investor relations material

Leadership and platform strengths

• Possesses a best-in-class gene editing platform and innovative allogeneic CAR-T technology, supported by strong intellectual property and know-how.

• Operates fully integrated, end-to-end in-house manufacturing facilities in both Europe and the U.S., enabling scalable production and controlled costs.

• Maintains diversified partnerships with industry leaders, offering significant financial upside through milestones and royalties.

Financial position and partnerships

• Cash position of $188M as of March 31, 2026, with expected runway into Q4 2027.

• Partnerships with Servier, Allogene, Iovance, and AstraZeneca provide multi-billion dollar milestone potential and royalties.

• Agreements include up to $2.8B in milestones and tiered royalties for various CAR-T and gene therapy programs.

Pipeline and clinical progress

• Four ongoing clinical trials: two fully owned and two with licensed partners, including pivotal Phase II and Phase I studies.

• Lead assets include Lasme-cel (CD22 CAR-T for B-ALL) and Eti-cel (dual CD20/CD22 CAR-T for NHL), both showing high response rates in relapsed/refractory settings.

• Pivotal Phase 2 interim analysis for Lasme-cel expected in Q4 2026; Eti-cel full Phase 1 dataset also expected in Q4 2026.